ClinicalTrials.gg
CompletedNCT04079530Updated Oct 6, 2025

A Clinical Pharmacology Study of K-877 Controlled Release Tablet

A Phase 2 interventional study of K-877 IR 0.2 mg/day and K-877 CR 0.4 mg/day in Dyslipidemias, sponsored by Kowa Company, Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-10-06.

Sponsored by Kowa Company, Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Dyslipidemias by Kowa Company, Ltd. — none open to participants now, none under way, none of them phase 3. Dyslipidemias · Kowa Company, Ltd..

Enrollment
16th of 20
60 · median 290
Started
2019
the only one that year
Phase 2
2 of 20
none open now
Registered
17th of 20
by date

Among the 20 studies in Dyslipidemias by Kowa Company, Ltd., this one is the 16th largest by enrollment, is the only one that started in 2019, is one of 2 in phase 2, and was the 17th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

None of the 20 studies in Dyslipidemias by Kowa Company, Ltd. is open now. The open studies under Dyslipidemias, anywhere →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies in Dyslipidemias by Kowa Company, Ltd. as a file.
02

Study summary

A study to compare the efficacy, safety, and pharmacokinetics of K-877 controlled release tablets with a current normal K-877 tablet in dyslipidemia.

03

Conditions studied

  • Dyslipidemias

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with dyslipidemia had to be age 20 years or older at written (ICF)
  2. Men and women.
  3. Patients who have received dietary or exercise guidance from 12 weeks prior to Screening.
  4. Patients who have clinical laboratory records with fasting serum TG ≥ 150 mg / dL (or ≥ 200 mg / dL if not fasting) within 6 months before written informed consent.
  5. Patients with a fasting serum TG ≥ 150 mg / dL at Screening.

Exclusion criteria

Exclusion Criteria:

  1. Patients with a fasting serum TG ≥ 500 mg / dL at Screening
  2. Patients who require administration of prohibited drugs during the clinical trial period after written
  3. Patients who have malabsorption or those who have had the history, or who have undergone other surgical procedures that may affect absorption (excluding appendectomy or hernia treatment etc)
  4. Patients with uncontrolled thyroid disease
  5. Patients with uncontrolled diabetes as defined by a (NGSP) ≥ 8.0% at Screening
  6. Persons with uncontrolled hypertension (SBP ≥ 160 mmHg or DBP ≥ 100 mmHg)
  7. Patients with an or ALT three times the upper limit at Screening
  8. Patients with cirrhosis or those with biliary obstruction
  9. Patients with malignant tumor or those who are judged to have a high risk of recurrence
  10. Patients who have collected 400 mL or more of whole blood within 16 weeks, or 200 mL or more of whole blood within 4 weeks, or blood samples (plasma and components) within 2 weeks before Screening
  11. Patients with a history of serious drug allergies (anaphylactic shock, etc.)
  12. Patients with a history of to pemafibrate, patients who have stopped taking pemafibrate for reasons of insufficient efficacy or safety
  13. Patients who participate in other clinical trials at the time of written informed consent or who have received clinical trials other than placebo for less than 16 weeks
  14. Patients who have been determined inappropriate by the investigator or subinvestigator
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Treatment A

    Period1:K-877 IR 0.2 mg/day, Period2:K-877 CR 0.4 mg/day (pre-meal)

    Drug: K-877 IR 0.2 mg/day · Drug: K-877 CR 0.4 mg/day

  • Experimental
    Treatment B

    Period1:K-877 IR 0.2 mg/day, Period2:K-877 CR 0.4 mg/day (postprandial)

    Drug: K-877 IR 0.2 mg/day · Drug: K-877 CR 0.4 mg/day

  • Experimental
    Treatment C

    Period1:K-877 IR 0.2 mg/day, Period2:K-877 CR 0.8 mg/day (pre-meal)

    Drug: K-877 IR 0.2 mg/day · Drug: K-877 CR 0.8 mg/day

  • Experimental
    Treatment D

    Period1:K-877 IR 0.2 mg/day, Period2:K-877 CR 0.8 mg/day (postprandial)

    Drug: K-877 IR 0.2 mg/day · Drug: K-877 CR 0.8 mg/day

  • Experimental
    Treatment E

    Period1:K-877 CR 0.4 mg/day, Period2:K-877 IR 0.2 mg/day (pre-meal)

    Drug: K-877 IR 0.2 mg/day · Drug: K-877 CR 0.4 mg/day

  • Experimental
    Treatment F

    Period1:K-877 CR 0.4 mg/day, Period2:K-877 IR 0.2 mg/day (postprandial)

    Drug: K-877 IR 0.2 mg/day · Drug: K-877 CR 0.4 mg/day

  • Experimental
    Treatment G

    Period1:K-877 CR 0.4 mg/day, Period2:K-877 CR 0.8 mg/day (pre-meal)

    Drug: K-877 CR 0.4 mg/day · Drug: K-877 CR 0.8 mg/day

  • Experimental
    Treatment H

    Period1:K-877 CR 0.4 mg/day, Period2:K-877 CR 0.8 mg/day (postprandial)

    Drug: K-877 CR 0.4 mg/day · Drug: K-877 CR 0.8 mg/day

  • Experimental
    Treatment I

    Period1:K-877 CR 0.8 mg/day, Period2:K-877 IR 0.2 mg/day (pre-meal)

    Drug: K-877 IR 0.2 mg/day · Drug: K-877 CR 0.8 mg/day

  • Experimental
    Treatment J

    Period1:K-877 CR 0.8 mg/day, Period2:K-877 IR 0.2 mg/day (postprandial)

    Drug: K-877 IR 0.2 mg/day · Drug: K-877 CR 0.8 mg/day

  • Experimental
    Treatment K

    Period1:K-877 CR 0.8 mg/day, Period2:K-877 CR 0.4 mg/day (pre-meal)

    Drug: K-877 CR 0.4 mg/day · Drug: K-877 CR 0.8 mg/day

  • Experimental
    Treatment L

    Period1:K-877 CR 0.8 mg/day, Period2:K-877 CR 0.4 mg/day (postprandial)

    Drug: K-877 CR 0.4 mg/day · Drug: K-877 CR 0.8 mg/day

Interventions

  • DrugK-877 IR 0.2 mg/day

    Drug page: Pemafibrate

    K-877 IR 0.1 mg tablet

    Also known as: Pemafibrate

  • DrugK-877 CR 0.4 mg/day

    Drug page: Pemafibrate

    K-877 CR 0.4 mg tablet

    Also known as: Pemafibrate

  • DrugK-877 CR 0.8 mg/day

    Drug page: Pemafibrate

    Two K-877 CR 0.4 mg tablet

    Also known as: Pemafibrate

06

What researchers measure

Primary outcomes

  1. Efficacy: % change from baseline in fasting serum TG(mg/dL)

    Time frame: 4 week after administration in each period

Secondary outcomes

  1. % change from baseline in fasting HDL-C levels(mg/dL)

    Time frame: 4 week after administration in each period

  2. % change from baseline in fasting LDL-C levels(mg/dL)

    Time frame: 4 week after administration in each period

  3. % change from baseline in fasting non-HDL-C levels(mg/dL)

    Time frame: 4 week after administration in each period

  4. % change from baseline in fasting Total Cholesterol levels(mg/dL)

    Time frame: 4 week after administration in each period

07

Study locations

1 site
  • Medical Corporation Heishinkai OPHAC Hospital
    Osaka, 532-0003, Japan
08

References and documents

Publications

  • Yamashita S, Araki E, Arai H, Yokote K, Tanigawa R, Saito A, Suganami H, Minamikawa S, Ishibashi S. Clinical Pharmacology of Pemafibrate Extended-release Formulation in Patients with Hypertriglyceridemia-A Phase 2, Multicenter, Active-controlled, Randomized, Single-blind, Crossover study. J Atheroscler Thromb. 2025 Mar 1;32(3):367-384. doi: 10.5551/jat.65001. Epub 2024 Sep 26. PubMed 39322570 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Dec 2019, 3 months.

Of 35 industry-sponsored phase 2 interventional studies under Dyslipidemias, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 3 months is below that.

Counting every sponsor, half of 43 studies reached it within 13 months; a quarter within 7 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2019
First posted
Sep 6, 2019
StartActual
Sep 13, 2019
Primary completionActual
Dec 24, 2019
CompletionActual
Dec 24, 2019
Last update
Oct 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04079530
Lead sponsor
Kowa Company, Ltd.
Responsible party
Sponsor
First posted
Sep 6, 2019
Start date
Sep 13, 2019
Primary completion
Dec 24, 2019
Completion
Dec 24, 2019
Last update
Oct 6, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemafibrate

Start the discussion